Evidence map›Paper›PMID 41994638›Full record

ArticleFrontiers in oncology2026

Metachronous bilateral renal cancer with immune checkpoint blockade-mediated eradication of bone metastasis: case report.

Dimitar Metodiev, Tsvetan Borisov, Pierre-Alexis Da Costa, Alaeddine Redissi, Isabelle Cremer, Mila Petrova, Yann A Vano, Lubka T Roumenina, Dilyan Ferdinandov

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dimitar MetodievClinical Pathology Laboratory, MHAT "Nadezda" Women's Health Hospital, Sofia, Bulgaria.
Tsvetan BorisovDepartment of Neurosurgery, Faculty of Medicine, Medical University of Sofia, Sofia, Bulgaria.
Pierre-Alexis Da CostaCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Alaeddine RedissiCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Isabelle CremerCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Mila PetrovaOncology Department, MHAT "Nadezda" Women's Health Hospital, Sofia, Bulgaria.
Yann A VanoCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Lubka T RoumeninaCentre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Université de Paris Cité, Team Inflammation, Complement and Cancer, Paris, France.
Dilyan FerdinandovDepartment of Neurosurgery, Faculty of Medicine, Medical University of Sofia, Sofia, Bulgaria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The immune landscape of renal cell carcinoma (RCC) is a key determinant of response to immune checkpoint inhibitors (ICIs). Yet, direct comparisons of immune infiltrates across histologic subtypes and metastatic sites within the same patient are rarely possible. Clinical case: A 71-year-old man underwent left-sided nephrectomy for clear cell RCC (ccRCC) in 2013. He developed a right-sided renal and liver-capsule lesion in 2024, with an enlarged paracaval lymph node. Partial right-sided nephrectomy, liver resection, and lymphadenectomy confirmed RCC with prominent sarcomatoid histology (sRCC). Chest CT and pelvic MRI scan did not detect metastases, but the cervical spine was not explored due to lack of symptoms. Two cycles of nivolumab plus ipilimumab were performed before discovering severe cervical spine pain. MRI identified a previously missed metastasis to the C4 vertebral body. Corpectomy achieved nearly complete tumor resection supplemented with fusion. Immunohistochemistry and multiplex immunofluorescence for PD-L1/CD3/CD20/CD163/C5aR1/CD31/CA9 were performed on primary tumors and metastases. Results: Here we show (1) robust CD3 Conclusions: This case illustrates that ICIs can induce near-complete eradication of bone metastases; that bone is not an immune-exempt organ, with massive intratumoral immune cell infiltration; and that immediate immune-mediated tumor clearance prevents structural skeletal damage, which merits careful surveillance.

Indexed as

bone metastasisimmune checkpoint inhibitorsrenal cell carcinomaSarcomatoid dedifferentiationtertiary lymphoid structurestumor immune microenvironment

Identifiers

PMID41994638
PMCPMC13078976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.